NCT02245867View on ClinicalTrials.gov

Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 30, 2014

Primary Completion Date

July 13, 2017

Study Completion Date

July 13, 2017

Conditions
AL Amyloidosis
Interventions
DRUG

Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4

The antibody binds to the pathologic material and initiates a neutrophil/macrophage response

Trial Locations (1)

10032

Columbia University Medical Center, New York

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY